MX2021015732A - Administracion intranasal de merotocina para mejorar la lactancia. - Google Patents

Administracion intranasal de merotocina para mejorar la lactancia.

Info

Publication number
MX2021015732A
MX2021015732A MX2021015732A MX2021015732A MX2021015732A MX 2021015732 A MX2021015732 A MX 2021015732A MX 2021015732 A MX2021015732 A MX 2021015732A MX 2021015732 A MX2021015732 A MX 2021015732A MX 2021015732 A MX2021015732 A MX 2021015732A
Authority
MX
Mexico
Prior art keywords
merotocin
intranasal administration
improving lactation
âμg
female
Prior art date
Application number
MX2021015732A
Other languages
English (en)
Inventor
Deborah Arbit
Saez Joan - Carles Arce
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MX2021015732A publication Critical patent/MX2021015732A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción se refiere al uso de una forma de dosificación novedosa de merotocina en el mejoramiento de la lactancia en una mujer necesitada de la misma. La descripción proporciona particularmente el uso de una composición adecuada para la administración intranasal que proporciona una dosis de merotocina mayor que 100 µg o en esencia aproximadamente 400 µg a la mujer. La descripción comprende métodos de tratamiento, así como también composiciones para el uso en estos métodos.
MX2021015732A 2019-11-04 2020-11-03 Administracion intranasal de merotocina para mejorar la lactancia. MX2021015732A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930427P 2019-11-04 2019-11-04
DKPA202000349 2020-03-18
PCT/EP2020/080831 WO2021089554A1 (en) 2019-11-04 2020-11-03 Intranasal administration of merotocin for improving lactation

Publications (1)

Publication Number Publication Date
MX2021015732A true MX2021015732A (es) 2022-01-24

Family

ID=73059927

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015732A MX2021015732A (es) 2019-11-04 2020-11-03 Administracion intranasal de merotocina para mejorar la lactancia.

Country Status (9)

Country Link
US (1) US20220313774A1 (es)
EP (1) EP4054521A1 (es)
JP (1) JP2023500763A (es)
KR (1) KR20220097360A (es)
CN (1) CN113950331A (es)
AU (1) AU2020380587A1 (es)
CA (1) CA3142709A1 (es)
MX (1) MX2021015732A (es)
WO (1) WO2021089554A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230143212A1 (en) * 2021-11-09 2023-05-11 Navinta, Llc Pharmaceutical Preparations Of Melatonin Suitable For Intranasal Administration

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101983205B (zh) 2008-03-31 2015-08-19 辉凌公司 催产素类似物
TWI463990B (zh) * 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
AU2010350241A1 (en) 2010-04-01 2012-10-25 The University Of Queensland Oxytocin peptide analogues
JO3400B1 (ar) 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules

Also Published As

Publication number Publication date
KR20220097360A (ko) 2022-07-07
CA3142709A1 (en) 2021-05-14
CN113950331A (zh) 2022-01-18
JP2023500763A (ja) 2023-01-11
WO2021089554A1 (en) 2021-05-14
US20220313774A1 (en) 2022-10-06
EP4054521A1 (en) 2022-09-14
AU2020380587A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
MY196319A (en) Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders
MX2019014514A (es) Compuestos para tratar la enfermedad de huntington.
MX2020007853A (es) Composiciones farmaceuticas para el tratamiento de fibrosis quistica.
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
MX2017016424A (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares.
GEP20207126B (en) New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2022005380A (es) Composiciones que comprenden colina.
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
NZ709803A (en) Compositions comprising 15-ohepa and methods of using the same
PH12020550616A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
MX2019007088A (es) Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
SG10201907289VA (en) Monomethylfumarate prodrug compositions
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer
MX2019012522A (es) Compuestos y metodos terapeuticos.
EA202191515A1 (ru) Фармацевтическая композиция, содержащая апиксабан
MX2023006677A (es) Composiciones para tratar la degeneracion macular seca relacionada con la edad (dme).
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
ZA202001568B (en) Methods and compositions for treating chronic lung diseases
MX2019003470A (es) Composicion farmaceutica y metodo para el tratamiento de la enfermedad del higado graso no alcoholico.
MX2021015732A (es) Administracion intranasal de merotocina para mejorar la lactancia.
MX2022003398A (es) Composicion micelar inmunoestimulante.
WO2018062876A3 (ko) 통증이 경감되는 골관절염 치료용 키트
PH12020500204A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease